JSPR (Jasper Therapeutics) Research & Development: $52.76 Mil (TTM As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
29 GF Score
Price $0.45
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Research & Development?

Jasper Therapeutics JSPR +8.45% 29 Research & Development is $52.76 Mil as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Jasper Therapeutics's Research & Development for the three months ended in Mar. 2026 was $5.81 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $52.76 Mil.

Jasper Therapeutics  (NAS:JSPR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Jasper Therapeutics Research & Development Related Terms

Jasper Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics Research & Development Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 25.42 34.63 51.79 55.82 63.10

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.16 21.20 14.39 11.36 5.81
JSPR
29GF Score
Jasper Therapeutics Inc JSPR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $52.76 Mil mean?
Jasper Therapeutics (JSPR) has a Research & Development of $52.76 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Jasper Therapeutics and its competitors.
Is Jasper Therapeutics' Research & Development too high?
Jasper Therapeutics' current Research & Development is $52.76 Mil. Overall, Jasper Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Research & Development compare to CVKD and BRTX?
Jasper Therapeutics' Research & Development of $52.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Jasper Therapeutics and its competitors. Jasper Therapeutics's current Research & Development is $52.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Research & Development of $52.76 Mil. The current Research & Development is $52.76 Mil. Jasper Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Research & Development is $52.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
29GF Score

Get the complete analysis for JSPR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price